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Abstract
Background: The variants of neuronopathic Gaucher disease may be viewed as a clinical phenotypic continuum
divided into acute and chronic forms. The chronic neuronopathic form of Gaucher disease is characterized by a
later onset of neurological symptoms and protracted neurological and visceral involvement. The first-choice
treatment for nonneuronopathic Gaucher disease is enzyme replacement therapy with recombinant analogues of
the deficient human enzyme glucocerebrosidase. Enzyme replacement therapy has been shown to improve
hematological and bone manifestations associated with Gaucher disease, but, as with most proteins, recombinant
enzymes cannot cross the blood–brain barrier, which prevents effects on neurological manifestations. Substrate
reduction therapy with miglustat (N-butyldeoxynojirimycin) inhibits glucosylceramide synthase, which catalyzes the
first step in glycosphingolipid synthesis. Because miglustat can cross the blood–brain barrier, it has been suggested
that, combined with enzyme replacement therapy, it might be effective in treating neurological symptoms in
patients with neuronopathic Gaucher disease.
Case presentation: We report observed effects of combined enzyme replacement therapy and substrate reduction
therapy in a 7-year-old Caucasian boy with neuronopathic Gaucher disease who was homozygous for L444P
mutations. He had received enzyme replacement therapy from the age of 18 months, and concomitant miglustat
treatment was commenced, with dosing according to body surface area uptitrated over 1 month with dietary
modifications when he reached the age of 30 months. He experienced mild diarrhea after commencing miglustat
therapy, which decreased in frequency/severity over time. His splenomegaly was reduced, and his hematological
values and plasma angiotensin-converting enzyme activity normalized. Plasma chitotriosidase also showed
substantial and sustained decreases. After 5 years of combination therapy, the patient showed no signs of
neurological impairment.
Conclusions: This case supports the concept that oral miglustat in combination with intravenous enzyme
replacement therapy may be beneficial in preventing neurological signs in patients with chronic neuronopathic
Gaucher disease. The importance of dietary modifications has also been confirmed. Further follow-up studies are
needed to better define the therapeutic effect of combined treatment in this Gaucher disease subtype.
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Background
Gaucher disease (GD) is one of the most common lipid
storage diseases, with a worldwide incidence of between
1:40,000 and 1:86,000 [1–3], but with a higher frequency
among Ashkenazi Jews [4]. GD is caused by a deficiency
of acid beta-glucosidase (glucocerebrosidase; GBA) due
to autosomal recessive inheritance of mutations in the
GBA gene (OMIM reference 606463). This enzyme defi-
ciency leads to accumulation of glucocerebroside—the
substrate of GBA—in cells of monocyte/macrophage
lineage, which then infiltrate the liver, spleen, bone marrow,
and other tissues with lipid-laden macrophages. Clinical
manifestations of GD include anemia; thrombocytopenia;
hepatosplenomegaly; skeletal disease; and, in some patients,
neurological involvement [5–8].
GD is usually classified into three phenotypes based
on the presence or absence and rate of progression of
neurological symptoms. GD type 1 (GD1) is by far the
most frequent subtype and does not feature any neuro-
logical manifestations [5]. GD type 2 (GD2), the acute
form of the disease, features severe neurological involve-
ment and early mortality, usually by the age of 2 years,
and GD type 3 (GD3) is characterized by a later onset of
neurological symptoms and a more protracted clinical
course [8, 9]. It is recommended that GD2 should be de-
scribed as acute neuronopathic Gaucher disease (NGD)
and GD3 as chronic NGD [10]. The major neurological
manifestation of chronic NGD is the early development
of horizontal supranuclear gaze palsy, which is typically
followed by progressive cognitive impairment, myoclonic
epilepsy, ataxia, and spasticity [9, 11].
There are two approved treatment modalities for GD.
Intravenous enzyme replacement therapy (ERT) is con-
sidered as the first-line therapy, comprising chronic
biweekly infusions of a recombinant analogue of human
enzyme GBA that catalyzes the hydrolysis of glucocereb-
roside to glucose and ceramide. ERT has been demon-
strated to improve hematological parameters (hemoglobin
concentrations and platelet counts), organomegaly, and
bone involvement [12, 13]. Oral substrate reduction
therapy (SRT) with the glucosylceramide synthase
inhibitor miglustat (N-butyldeoxynojirimycin) is con-
sidered as a second-line treatment option for those
patients with mild to moderate GD1 for whom intra-
venous ERT is unsuitable [14, 15].
It must be noted that, because they are proteins, re-
combinant enzymes do not cross the blood–brain bar-
rier and consequently have been shown to have little
effect on neurological disease manifestations in NGD
[10, 16]. In contrast, the small-molecule iminosugar
miglustat has been shown to have a wide tissue distribu-
tion and a partial ability to cross the blood–brain barrier
[17, 18]. On the basis of these chemical properties,
miglustat was approved for the treatment of progressive
neurological manifestations in adult and pediatric
patients with the progressive neurodegenerative con-
dition Niemann-Pick disease type C [15]. To date,
mixed results have been reported with miglustat in
patients with chronic NGD [19–21]. We report a case
of a pediatric patient, aged 7 years, with chronic
NGD who received early treatment with combination
ERT-SRT.
Case presentation
Our patient was a 7-year-old Italian boy born after an
uneventful gestation of normal duration. At the age of
16 months, he presented with a clinically evident en-
larged abdomen and was referred for oncological exam-
ination. Initial tests revealed anemia, thrombocytopenia,
and splenomegaly. A bone marrow biopsy revealed the
presence of foam cells, which led to suspicion of lyso-
somal storage disease. Biochemical testing revealed ele-
vated level of acid phosphatase (47.8 IU/L [normal range
5–7 IU/L]) and chitotriosidase activity (508 nmol/mg
protein [normal range 5.9–41.0 nmol/mg protein]), as
well as reduced beta-glucosidase activity (2 nmol/mg/
protein [normal range 4.5–18.0 nmol/mg/protein]).
Molecular analysis showed homozygous L444P mutations
in the GBA gene (OMIM reference 606463), confirming
the diagnosis of chronic NGD.
The patient began ERT at a dosage of 60 U/kg every 2
weeks at the age of 18 months. Thereafter, when the pa-
tient reached the age of 30 months, we decided to com-
bine ERT with SRT with miglustat. This clinical decision
was approved by our institution’s ethics committee, and
informed consent was obtained from the patient’s par-
ents before commencing combination therapy. The dose
of miglustat was adjusted according to the patient’s body
surface area and was uptitrated during the first 4 weeks
with the following scheme: one-third of target dose dur-
ing weeks 1 and 2, two-thirds of target dose during
weeks 3 and 4, and target dose (100 mg three times
daily) after 1 month. From 2 weeks before starting
miglustat therapy, the patient also followed specific diet-
ary modifications, avoiding high intake of carbohydrate-
containing food in single meals, especially foods high in
disaccharides, such as sucrose and maltose, to ensure
acceptable gastrointestinal tolerability. He experi-
enced mild episodes of diarrhea after commencing
miglustat therapy, which decreased in frequency/se-
verity over time.
From the start of ERT/miglustat combination treat-
ment, we observed a reduction in splenomegaly and a
gradual normalization of hematological values and
plasma angiotensin-converting enzyme activity (Table 1).
Plasma chitotriosidase was evaluated at the time of
diagnosis and then approximately every 6 months
during follow-up. Values showed an initial reduction
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after the start of ERT, with a further, substantial, and
sustained decrease after commencement of miglustat
treatment (Fig. 1).
The patient has been followed according to recom-
mended guidelines for GD, which specify a complete
neurological examination, clinical evaluation of ocular
movements, and psychological evaluations every 6–12
months [10]. After 5 years of combination therapy
and follow-up, the patient did not show any signs of
neurological impairment. As of February 2016, he had
not displayed any epileptic crises and had demonstrated
clinical performance and cooperation. He showed good
muscular tone and trophism, normal reflexes with a slight
hyperreflexia in his legs, and a negative Romberg sign.
His toe and heel deambulation was normal. In
particular, ocular evaluations revealed no evidence of
saccadic movement velocity reduction and normal vis-
ual evoked potentials. The patient’s auditory brain
responses were also normal. In addition, he has not
demonstrated any cognitive impairment, and he has
regularly attended school with good performance
since the age of 5 years.
Table 1 Hematological and spleen parameters over time on treatment
Age, months (time point) Hb (g/dl) PLT (×103 μl) MCV (fl) ACE (U/L) Spleen diameter (cm)
17 (diagnosis) 10.7 185 60.3 – Enlarged
18 (ERT) 10.5 123 70.6 110 10.4
24 (SRT) 12.2 289 67.5 – 11.0
32 12.3 225 71.1 90 9.5
39 12.7 222 70.6 – –
45 12.3 246 74.9 90 9.7
51 12.7 256 79.6 – –
59 12.7 342 74.6 75 8.8
65 12.4 235 75.4 – –
72 12.8 261 77.4 48 9.5
80 13.5 312 78.7 – –
Hemoglobin (Hb), platelets (PLT), median corpuscular volume (MCV), angiotensin-converting enzyme (ACE) activity, and echographic measures of spleen diameter were
evaluated approximately every 6 months (12 months for ACE and spleen diameter after the first year on therapy). The data showed an improvement in all parameters
Fig. 1 Plasma chitotriosidase over time on treatment. Chitotriosidase values were evaluated approximately every 6 months. These data showed a
reduction in plasma values after the start of combination therapy. ERT Enzyme replacement therapy, SRT Substrate reduction therapy
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Discussion
According to revised recommendations, NGD can be
defined as the presence of neurological involvement in a
patient with biochemically proven GD [10]. Neuronopathic
forms are the rarest variants of GD, although some clusters
of high prevalence have been reported, such as that in
Norrbotten, Norway, which, unlike nonneuronopathic GD
type 1, is not associated with Jewish ancestry [3, 5]. The
GBA gene is located on chromosome 1q21, and around
400 mutations have been identified that are associated with
GD and Parkinson’s disease [22]. Most of these occur in the
homozygous state. Our patient carries an L444P/L444P
genotype that typically leads to a chronic neurological
phenotype [6, 23, 24].
The first clinical signs of neurological involvement in
patients with chronic NGD typically appear at a median
age of 2 years and worsen with time [6], and L444P-
homozygous patients generally show at least one sign of
neurological involvement during the early stage or late in-
fantile stage of life [6, 23–25]. In contrast, our patient did
not show any neurological symptoms up to his last clinical
visit (aged 7 years). This finding is in contrast with our
own clinical records of five older patients with the same
genotype from a limited geographical area, all of whom re-
ceived ERT as monotherapy and who presented with
neurological impairment during the first 5 years of life.
Positive effects of ERT/SRT combination therapy were
first described in 2007 in a 32-year-old patient treated
for 2 years with miglustat 200 mg three times daily in
addition to ERT (imiglucerase) at a dosage of 60 IU/kg
every 2 weeks [19]. The patient showed his first neuro-
logical signs at age 22 years. His neurological condition
gradually worsened despite ERT, which was increased in
dosage to 240 IU/kg every 2 weeks after 5 years. Before
the introduction of miglustat, this patient experienced
frequent multifocal myoclonic jerks (up to 50 general-
ized seizures per day) as well as severe dystonia in his
arms and legs, which confined him to a wheelchair.
After 2 years of combination therapy, there was a
marked improvement in his neurological status, includ-
ing a reduction in seizure frequency to approximately
ten per day. In addition, his dystonia improved, and he
was no longer confined to a wheelchair.
Other studies have attempted to assess the effectiveness
of combination therapy with miglustat plus ERT in NGD,
but mixed results have been reported so far. In a 24-
month randomized controlled trial with 30 patients with
chronic NGD, researchers compared miglustat plus ERT
(n = 21) with ERT alone (n = 9) on the basis of changes in
vertical saccadic eye movement (VSEM) velocity from
baseline [26]. No significant differences were observed be-
tween the treatment groups in VSEM velocity or other
secondary neurological parameters, but combination
treatment did appear to have a positive effect on
pulmonary function and chitotriosidase activity. Although
the unexpected positive effect on pulmonary function
could justify, by itself, combination treatment with miglu-
stat and ERT, particularly in patients with lung involve-
ment, the neurological findings were not conclusive and
left some questions unresolved. First, all patients enrolled
in the trial had a reduced VSEM velocity. The lack of
asymptomatic patients makes it impossible to determine
with certainty the ineffectiveness of combination therapy
for the prevention of neurological symptoms. Second, the
24-month observation period was likely too short to iden-
tify a therapeutic response in terms of VSEM [26].
Authors of a case series reported findings with combin-
ation therapy in three siblings with chronic NGD, all of
whom were homozygous for the L444P mutation [27]. The
ages of the patients at initiation of combination treatment
were 14 years, 10 years and 5 months, respectively. The
youngest patient received miglustat in an early stage of the
disease, at which point he exhibited only disturbed VSEM
and did not show any neurological signs after 3.5 years of
therapy. The other patients, who had more established dis-
ease and had demonstrated significant neurological impair-
ments from the age of 1.5 years, did not show any
neurological improvement. The authors indicated that initi-
ation of combination treatment early in the course of NGD
might actually prevent, or at least delay, neurological symp-
tom onset, and that demonstrating neurological improve-
ments in patients with established impairments might be
more difficult and/or take longer [27].
Potential beneficial effects of miglustat monotherapy on
neurological signs in NGD have also been reported by
Accardo and colleagues on the basis of their findings in two
sisters with the same genotype (R353G/R353G) who pre-
sented with late-onset NGD [21]. Both patients were
switched from ERT to miglustat, and both had received
barbiturates for control of epileptic seizures [21]. One of
the sisters developed oculomotor signs with a VSEM peak
velocity reduction (259 degrees/second) that improved (851
degrees/second) after 2 years of therapy with miglustat.
The gastrointestinal tolerability profile of miglustat in
our patient was in line with previous published data
[28, 29]. Miglustat acts through reversible inhibition
of intestinal disaccharidase enzymes (sucrase and
maltase) and very mild interference with lactase,
which together lead to impaired gastrointestinal
carbohydrate absorption and subsequent osmotic diar-
rhea [28, 30]. In our experience, dietary modifications
to reduce the ingested carbohydrate load during drug
uptitration in the first month of therapy can improve
the gastrointestinal tolerability of miglustat.
Conclusions
This case supports the concept that the addition of oral
miglustat to ongoing intravenous ERT may help prevent
Ceravolo et al. Journal of Medical Case Reports  (2017) 11:19 Page 4 of 5
neurological deterioration in patients with chronic NGD.
The importance of dietary modifications has also been
confirmed. Further follow-up studies are needed to bet-
ter define the therapeutic effect of combined treatment
in this GD subtype.
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